期刊文献+

维持性血液透析患者他汀类调脂治疗 被引量:2

Advancement in statin regimens in patients undergoing maintenance hemodialysis
下载PDF
导出
摘要 脂代谢紊乱是诱发心脑血管事件的重要危险因素,已有大量研究证实,应用他汀类药物调脂治疗对心脑血管的保护作用。维持性血液透析(MHD)患者常伴严重的脂代谢异常,心脑血管疾病亦是MHD患者的主要死亡原因。因此,他汀类药物能否降低MHD患者心脑血管事件的发生率及相关死亡率已成为近来研究热点之一。本文对他汀类药物应用于MHD患者的临床研究进展作一综述。 The patients with maintenance hemodialysis (MHD) are associated with accelerated atherosclerosis and increased morbidity and mortality frown cardiovascular disease.MHD patients are characterized by a complex plasma dyslipoproteinemic profile.Statin therapy has been proved to reduce the incidence of cardiovascular events and mortality in diverse patient populations at increased risk.There has been concern about the efficacy and safety of statin in MHD patients.This review will focus on the relevant progresses of statin therapy in patients undergoing MHD treatment.
出处 《肾脏病与透析肾移植杂志》 CAS CSCD 北大核心 2013年第4期373-379,共7页 Chinese Journal of Nephrology,Dialysis & Transplantation
关键词 维持性血液透析 心血管疾病 他汀类药物 maintenance hemodialysis cardiovascular disease statin
  • 相关文献

参考文献45

  • 1Samak M J,Levey AS,Schoolwerth AC,et al.Kidney disease as a risk factor for development of cardiovascular disease:a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease,High Blood Pressure Research,Clinical Cardiology,and Epidemiology and Prevention.Circulation,2003,108 (17):2154-2169.
  • 2Vanholder R,Massy Z,Argiles A,et al.Chronic kidney disease as cause of cardiovascular morbidity and mortality.Nephrol Dial Transplant,2005,20 (6):1048-1056.
  • 3USRenal Data System.USRDS 2012 annual data report.http://www.usrds.org/2012/slides/indiv/v2index.htm.
  • 4Stenvinkel P.Chronic kidney disease:a public health priority and harbinger of premature cardiovascular disease.J Intern Med,2010,268 (5):456-467.
  • 5Liu Y,Coresh J,Eustace JA,et al.Association between cholesterol level and mortality in dialysis patients:role of inflammation and malnutrition.JAMA,2004,291 (4):451-459.
  • 6Baigent C,Keech A,Kearney PM,et al.Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.Lancet,2005,366 (9493):1267-1278.
  • 7Ford l,Murray H,Packard CJ,et al.Long-term follow-up of the West of Scotland Coronary Prevention Study.N Engl J Med,2007,357(15):1477-1486.
  • 8Ridker PM,Danielson E,Fonseca FA,et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med,2008,359(21):2195-2207.
  • 9Konstantinos M,Lipids and diabetes//Katsilambros N,Diakoumopoulou E,Ioannidis I,et al.Diabetes in Clinical Practice:Questions and Answers from Case Studies.John Wiley & Sons,Ltd.2006:293-297.
  • 10Shoji T,lshimura E,Inaba M,et al.Atherogenic lipoproteins in endstage renal disease.Am J Kidney Dis,2001,38(4 Suppl 1):S30-33.

同被引文献10

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部